Galderma Group AG has agreed to acquire ZO Skin Health for $1.5 billion in an all-cash deal, the Swiss dermatology company announced on October 14, 2026 — its biggest acquisition since listing on the Swiss stock exchange in early 2024. The move plants Galderma firmly in the fast-growing physician-dispensed, medical-grade skincare market.
The $1.5 billion deal
Reuters broke the story on October 14 before Galderma confirmed it the same day: the company signed an agreement to acquire 100% of ZO Skin Health at an enterprise value of $1.5 billion, funded entirely in cash. The sellers include funds managed by Blackstone Tactical Opportunities, which bought a majority stake in ZO in 2020 for an undisclosed sum, and the founding Obagi family.
The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals, and Galderma says it will be neutral to its core earnings per share in the first full year after closing.
What ZO Skin Health brings
ZO Skin Health was founded by dermatologist Dr. Zein Obagi and is headquartered in Irvine, California. With more than two decades in clinically-backed professional skincare, the company makes 40-plus products in the United States and sells through 16,500-plus physician, medical-spa and online accounts across more than 40 countries. Net sales reached about $330 million in the 12 months to June 2026.
Galderma, based in Zug, Switzerland and listed as SIX: GALD, owns Cetaphil, Alastin and the Dysport/Restylane aesthetics brands. L'Oreal holds a 20% stake. The company opened a U.S./Latin America headquarters in Miami in August 2026 and plans to invest more than $650 million in American manufacturing through 2030.
Why Galderma wants it — and how markets reacted
Chief executive Flemming Ørnskov told Reuters: "We like the science, we like the location… They're stronger in med spas than we are. We're more dermatologists and plastic surgeons." The official statement called the deal "another important step towards building the world's most innovative dermatology portfolio" with "significant opportunities to reignite its growth through investment in innovation and commercial reach." Reuters notes the physician-dispensed skincare segment grows about 5–8% a year.
Analysts welcomed the fit. Vontobel's Stefan Schneider said the complementary portfolios are "a perfect fit," while Jefferies' Benjamin Jackson said the acquisition "meaningfully expands Galderma's exposure to the physician-dispensed, medical-grade skincare channel." One analysis put the price at an enterprise-value-to-sales multiple of about 4.5 times. Galderma shares dipped around 1.1% in early Zurich trading on the news after rising roughly 20% over the prior 12 months.
The takeaway
At $1.5 billion, Galderma is paying up for growth in medical-grade skincare — betting that ZO's physician network and science-led brand can be scaled globally through its dermatology reach. If the Q4 2026 closing holds, the combined portfolio becomes one of the strongest in professional skincare overnight.
Music in this post's reel: Kevin MacLeod - Long Road Ahead (incompetech.com), licensed under CC BY 3.0